Novo Nordisk
14 articles
Industry NewsNovo NordiskBioPharma Dive
Novo files etavopivat for sickle cell disease in the US and Europe
- Novo Nordisk has submitted US and European marketing applications for etavopivat, a once-daily oral treatment for sickle cell disease.
- The drug came from the roughly $1 billion Forma Therapeutics acquisition; Novo describes it as a potential new standard of care and a future blockbuster.
- Etavopivat is also in mid-stage testing for thalassemia.
For a company defined by obesity, a rare-disease filing is a quiet portfolio hedge, and an oral once-daily option fits a market still dominated by infusions and gene therapies. The comparison that matters is with Agios's mitapivat, another PK activator moving toward sickle cell: no head-to-head exists, so label wording on crisis reduction versus haemoglobin response will decide positioning.
Industry NewsNovo Nordisk / Eli LillyBioSpace
FDA orders class-wide GLP-1 label update for potential risk of rare eye disease
- FDA is requiring all approved GLP-1 receptor agonists to add a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION) to Warnings and Precautions; indications are unchanged.
- Twelve products are affected, including Wegovy, Ozempic, Zepbound and Mounjaro.
- A trial meta-analysis found 6.4 NAION events per 100,000 patient-years with GLP-1s versus 3.8 for comparators; FDA found no mechanism in animal data.
A Warnings-section addition rather than a boxed warning keeps the commercial hit modest, and the absolute difference is small. Still, class-wide wording denies Novo and Lilly any differentiation on eye safety. What's missing is mechanism and per-drug data; watch for ophthalmology-driven prescribing caution in high-risk patients.
Industry NewsNovo NordiskSTAT News
Novo's Ziltivekimab Fails ZEUS, but Cardiologists Keep Chasing Inflammation
- Full ZEUS results were discussed at the AHA meeting. The once-monthly IL-6 antibody did not cut major cardiovascular events in patients with atherosclerotic disease, kidney disease and elevated inflammation, even though it lowered IL-6 and hsCRP as intended.
- Serious infections were more frequent on drug, Novo is taking a non-cash impairment, and the heart failure (HERMES) and post-heart-attack (ARTEMIS) trials continue, reading out in the first half of 2027.
A clean target-engagement miss is the worst case for IL-6: the biomarker moved and outcomes did not, which undercuts hsCRP as a surrogate for patient selection. Colchicine and Novartis's IL-1β precedent keep the inflammation thesis alive, but HERMES and ARTEMIS now carry the whole franchise, and an infection signal is a hard thing to net against a modest benefit.
Industry NewsNovo NordiskEndpoints News
Novo Says CagriSema Won't Launch in Europe for a Couple of Years
- Novo Nordisk's outgoing CFO, Karsten Munk Knudsen, told Endpoints that CagriSema will not launch in Europe for another "couple of years."
- Novo's third-quarter report says it is preparing for a US launch in early 2027, subject to regulatory approval.
A US-first, Europe-later sequence for the company's most important obesity follow-up is a notable choice when Lilly's tirzepatide is already established in European markets. The snippet doesn't say whether supply, reimbursement or regulatory timing drives it; that is the thing to find out, because the reason decides whether it is a one-region delay or a template for later launches. It is also a statement from a departing executive, so treat the timeline as indicative.
Industry NewsEli Lilly / Novo NordiskBioPharma Dive
Lilly's Retatrutide Tops Ozempic Head-to-Head in Type 2 Diabetes
- Lilly's Phase 3 TRANSCEND-T2D-2 pitted triple-agonist retatrutide against Ozempic 2 mg in roughly 1,300 adults with type 2 diabetes over 80 weeks, and hit its primary and key secondary endpoints.
- Both retatrutide doses cut A1C more than Ozempic and produced about twice the weight loss; the top dose carried more side effects and discontinuations.
- The trial was open-label and the data are company topline; Lilly plans regulatory filings in early 2027.
A head-to-head win over the diabetes market's reference product is the evidence payers and prescribers have been waiting for, and it lands on Novo's home turf rather than in obesity. The tolerability gap at the top dose is the caveat to watch: if dropouts hold up in full data, the 9 mg dose may be the commercial workhorse.
Industry NewsNovo Nordisk / Eli LillyBioPharma Dive
Judge Won't Pull Lilly's Obesity Ads as Novo Fails to Show Harm
- A federal judge refused Novo Nordisk's request for a preliminary injunction against Lilly's comparative Zepbound advertising.
- Novo failed to show harm: Wegovy prescriptions held steady during the April-July campaign, and the ads acknowledged a higher-dose Wegovy exists.
- Novo says the order does not decide whether the ads are false; its July false-advertising suit continues.
Flat Wegovy prescriptions through a months-long Lilly campaign is the quiet finding: it undercuts the idea that comparative messaging is moving share in obesity, and shows how hard injunctions are to win without measurable harm. The July suit still runs, but in a two-player GLP-1 market, expect the real contest to stay on data and access, not in court.
Industry NewsNovo Nordisk / Orbis MedicinesEndpoints News
Novo bets up to $1.4B on Orbis's oral macrocycle platform
- Orbis Medicines signed a multi-target discovery and license deal with Novo Nordisk worth up to $1.4B in upfront and milestone payments plus tiered royalties.
- Novo also takes a strategic equity stake in the private Copenhagen company; this is Orbis's first pharma partnership.
- The work uses Orbis's AI-enabled nGen platform to make macrocycles aimed at turning injectable cardiometabolic therapies into orals.
- Orbis reported preclinical oral bioavailability up to 18%; targets and disease areas beyond cardiometabolic were not disclosed.
This is Novo hedging its oral strategy beyond small-molecule GLP-1s and oral semaglutide: macrocycles are the bet that peptide-like potency can survive the gut. The headline number is mostly milestones, so the real signal is the equity stake and a multi-target structure that lets Novo test the platform cheaply. Lilly is also an Orbis backer, which tells you both obesity leaders want the same oral-peptide option.
Industry NewsNovo Nordisk / Jiangsu Hengrui PharmaceuticalsEndpoints News
Novo Pays $300M Upfront for Hengrui's Weekly Oral GLP-1/GIP Agonist
- Novo gets exclusive rights outside mainland China, Hong Kong, Macau and Taiwan to HRS-1596, a once-weekly oral GLP-1/GIP dual agonist, for $300M upfront and up to $2.3B in milestones plus royalties.
- The asset is Phase 1-ready, with Chinese clearance to start trials in weight management and type 2 diabetes; closing is expected in Q4 2026.
Paying $300M upfront for a molecule that hasn't dosed a human outside China shows how badly Novo wants an oral follow-on while Lilly presses its lead. It also fits a pattern of buying de-risked-enough optionality from outside rather than building it, after smaller deals like Nanexa. Weekly oral bioavailability is the real technical risk, and the milestone-heavy structure shields Novo if it fails.
Industry NewsNovo Nordisk / NanexaEndpoints News
Novo Nordisk Taps Nanexa's Nanocoating Tech for Long-Acting Obesity Shots
- Novo Nordisk signed a global licensing deal with Swedish biotech Nanexa for its ALD-based PharmaShell platform, which coats drug particles to control release.
- Covers up to five programs in obesity, diabetes and cardiometabolic disease, aiming for monthly/quarterly dosing versus more frequent injections.
- Worth up to €1.165B, with ~€615M upfront/milestones plus royalties; Nanexa shares more than doubled.
Novo again chooses a capital-light platform bet over a big asset buy: licensing unproven ALD nanocoating across five programs to chase Lilly's once-monthly ambitions, since monthly dosing is what keeps patients on therapy once oral GLP-1s and biosimilars start undercutting Wegovy on convenience. Tellingly, ~€615M upfront/milestones against a €1.165B ceiling means Nanexa, not Novo, fronts most of the technical risk until PharmaShell proves out in humans.
Industry NewsNovo NordiskSTAT News
Novo Nordisk May Have Landed a Sweeter Deal in Medicare's GLP-1 Bridge Pilot
- Medicare's GLP-1 Bridge pilot, launched under the Trump administration, sets a flat $50 monthly co-pay for obesity drugs — including Novo Nordisk's Wegovy and Eli Lilly's Zepbound and orforglipron — for Part D beneficiaries from July 2026 to December 2027.
- STAT reporting suggests Novo Nordisk's negotiated terms under the pilot may be more advantageous than initially disclosed, potentially outperforming Lilly's arrangement.
A pricing edge over Lilly in this two-horse race is worth more than the headline $50 co-pay — share captured under a fixed-price pilot compounds fast, and better fine print (rebates, volume triggers) beats a flashier price point. Read this as both companies treating government-negotiated terms as a template to refine, not a one-off concession, ahead of oral GLP-1 competition.
Industry NewsNovo NordiskSTAT News
Novo Nordisk Unveils 2030 Growth Strategy at Capital Markets Day; Shares Slide on Thin Details
- At its Sept. 21, 2026 Capital Markets Day in London, new CEO Mike Doustdar unveiled a strategy to scale Novo Nordisk's obesity franchise and diversify the pipeline beyond diabetes/obesity.
- Targets include 10x capacity for oral GLP-1 obesity therapy, serving more than 60 million patients globally by 2030, and launching 5+ "multi-blockbuster" products by 2030.
- Novo also set a goal of more than DKK150 billion (about $23 billion) in risk-adjusted pipeline sales by 2035, and pledged to be "more active" in business development (licensing/M&A) and direct-to-consumer sales models.
- The moves are aimed at addressing investor concern that Novo is too reliant on its GLP-1 franchise.
- Market reaction was negative: shares fell sharply intraday (reports of roughly 5-9%), as analysts said the plan was strong on ambition but thin on new specifics, amid rising competition from Eli Lilly's tirzepatide/Zepbound.
This is the payoff to last week's "Novo" rebrand, and the market just delivered its verdict: a 2030/2035 target set with no concrete near-term catalyst is guidance, not proof, so shares got sold rather than bought. The real signal isn't the capacity or blockbuster math — it's the pledge to get "more active" in business development. That's Doustdar admitting the internal pipeline can't diversify fast enough on its own, especially with Lilly's tirzepatide/Zepbound machine still taking share while Novo's oral GLP-1 scale-up remains years out. Ambition claims parity; execution proves it. The next real test isn't another investor-day slide — it's whether Doustdar actually closes a deal or lands an R&D readout in the coming quarters, or whether this was sentiment management dressed up as strategy.
Industry NewsNovo NordiskFiercePharma
Novo Nordisk Rebrands as 'Novo' in Public-Facing Identity Shift
- Novo Nordisk announced on September 14, 2026 that it will use "Novo" as its public-facing brand name, dropping "Nordisk" from consumer-facing communications; the legal corporate name, Novo Nordisk A/S, is unchanged.
- The rebrand includes a new tagline, "Lasting Health Starts Now," a refreshed internal culture framework called "The Novo Way," and an updated version of the company's Apis bull logo, now facing forward.
- CEO Mike Doustdar, roughly a year into his tenure, is leading the rebrand as part of a broader corporate turnaround and simplification strategy.
- The move comes amid intensifying competition in the GLP-1/obesity drug market and recent stock pressure.
- The announcement was timed ahead of the company's capital markets day, scheduled for September 21, 2026.
Timing is the tell: a name change lands seven days before capital markets day, and rebrands are the cheapest lever a new CEO can pull — no pipeline risk, no payer negotiation, no manufacturing capex. Doustdar needs the CMD to convert cosmetics into substance: a credible answer to Lilly's tirzepatide share gains and Zepbound pricing pressure, a pipeline update beyond semaglutide (oral GLP-1, amycretin, next-gen combos), and cost detail that shows "simplification" is more than messaging. Watch three things at CMD: guidance revisions, R&D readouts with real differentiation, and whether "The Novo Way" comes with organizational or capital-allocation changes, not just culture-deck language. If the identity refresh isn't paired with share-defending data, it's a signal management is managing sentiment, not fundamentals.
Industry NewsNovo Nordisk / Ascendis PharmaFierce Biotech
Novo Nordisk Exits $285M Obesity Drug Deal with Ascendis Pharma
- Novo Nordisk has terminated its partnership with Ascendis Pharma to co-develop a once-monthly GLP-1 receptor agonist for obesity and diabetes.
- The collaboration was signed in November 2024 and licensed Ascendis's TransCon sustained-release drug delivery platform to Novo for its lead once-monthly program.
- Under the original agreement, Ascendis was eligible for up to $285 million in combined upfront, development, and regulatory milestone payments, plus potential tiered royalties.
- The goal was a monthly-dosed treatment intended to compete with existing daily and weekly GLP-1 drugs on the market.
- Novo ended the collaboration less than two years after it began, with no monthly GLP-1 product having resulted from the partnership.
A sub-$300M deal dying in under two years, with no candidate ever reaching the clinic, is a cheap off-ramp — Novo exits with minimal sunk cost, unlike a late-stage termination. That's the tell: this reads less as a verdict on Ascendis's TransCon chemistry and more as Novo reprioritizing internally under intense competitive pressure from Lilly's tirzepatide franchise and oral orforglipron. Killing a monthly-dosing bet also raises a sharper question: is weekly GLP-1 dosing already "good enough," with the real prize shifting to oral convenience instead? For Ascendis, the financial hit is small but the strategic one isn't — losing a big-pharma validation partner for TransCon undermines the platform story just as investors want proof the delivery tech, not just the molecule, is what pharma will pay up for.
Industry NewsNovo NordiskEndpoints News
Novo Nordisk halts two more ziltivekimab heart trials on futility finding
- Novo Nordisk is stopping two Phase 3 trials, HERMES and ATHENA, of ziltivekimab early after a data monitoring committee flagged futility.
- Ziltivekimab is an antibody that targets interleukin-6 (IL-6), an inflammatory cytokine, and the trials were testing it in heart failure patients with inflammation.
- The committee concluded neither trial was likely to produce a different result from the earlier Phase 3 ZEUS trial, which missed its cardiovascular endpoint in July.
- HERMES tracked time to cardiovascular death or heart failure-related hospitalization/urgent visits; ATHENA measured broader heart failure outcomes including quality of life.
- Novo Nordisk is continuing a separate Phase 3 trial, ARTEMIS, testing ziltivekimab as an acute post-heart-attack treatment, with a readout expected in the first half of 2027.
- The repeated failures raise doubts about IL-6 inhibition as a viable cardiovascular treatment strategy.
Three strikes on cardiovascular endpoints now — ZEUS in July, HERMES and ATHENA today — and Novo isn't spinning this as a design problem anymore; the DMC futility call is about as clear a kill signal as you get. Sunk cost here isn't trivial: ziltivekimab was Novo's flagship diversification bet outside GLP-1s, and this guts the broader inflammation-in-CV thesis that Novartis also struggled to validate with canakinumab post-CANTOS. IL-6 as a druggable node for heart failure now looks structurally shaky, not just underpowered. ARTEMIS surviving to 2027 reads less like conviction and more like sunk-cost inertia — acute post-MI biology differs, but a quiet wind-down before readout wouldn't surprise me if enrollment softens. Zoom out and this underscores just how thin Novo's non-GLP-1 pipeline really is, right as obesity/diabetes competition intensifies.